FDA Brief

Warning letters Drugs

FDA warning letter to

Clean Solutions LLC

High riskIssued Sep 6, 2024Posted Oct 1, 2024Division of Pharmaceutical Quality Operations I

FDA warned Clean Solutions LLC that its OTC hand soaps and sanitizer were adulterated because it released drugs without component or finished-product testing.

What happened

FDA inspected Clean Solutions LLC in Clifton, NJ, from May 6 to 10, 2024. FDA found the firm did not test component identity or finished batches, did not validate processes or qualify equipment, and lacked adequate quality-unit oversight. FDA said the May 29, 2024 response was inadequate because it lacked supporting documentation or adequate evidence of corrective actions.

What FDA found

  1. The firm did not test each component lot to confirm identity and relied on suppliers' certificates of analysis without checking the suppliers' test reliability.

    21 CFR 211.84(d)(1) and (2)
  2. The firm did not test each finished drug batch for identity and strength of active ingredients or for objectionable microorganisms before release.

    21 CFR 211.165(a) and (b)
  3. The firm lacked written production and process control procedures and had not validated its manufacturing processes or qualified its equipment.

    21 CFR 211.100(a)
  4. The quality control unit did not ensure adequate complaint handling, change control, training, stability testing, annual product reviews, cleaning and cleaning validation, or batch records.

    21 CFR 211.22; 211.22(d); 211.166(a); 211.180(e); 211.67(a),(b); 211.188(b)

What FDA wants

Respond in writing within 15 working days, state what you have done to correct the violations and prevent recurrence, and if corrective actions are not complete, give reasons and a schedule. FDA also asks the firm to clarify whether it will continue making drugs and recommends a qualified CGMP consultant and a six-system audit if it does.

Who should pay attention

  • retailers and distributors selling OTC hand soaps or sanitizers
  • brands using contract manufacturers for topical OTC drugs
  • suppliers of benzalkonium chloride or other drug components

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. TCI Co., Ltd BioCosme PABP BRANCH

    FDA warns Taiwan OTC drug contract manufacturer TCI BioCosme over CGMP violations, including incomplete release and ingredient testing.

    High risk
  3. Babikian Healthcare Products CJSC

    FDA warns Babikian Healthcare Products over manufacturing quality failures for over-the-counter drugs, including missing identity and finished-product testing.

    High risk
  4. Stream2Sea, LLC

    FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.

    Medium